EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Emerging Therapeutic Approaches to Pancreatic Adenocarcinoma: Advances and Future Directions

Chengwei Peng, Paul E Oberstein

Current Treatment Options in Oncology · 2025-10 · 26 (10) · 841-865

DOI: 10.1007/s11864-025-01352-2 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Treatment Options in Oncology, online erschienen am 30.08.2025. Verfasst von Chengwei Peng und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. Chengwei.peng@northwestern.edu. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Adenocarcinoma. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 182 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Opinion Statement Pancreatic adenocarcinoma remains a leading cause of cancer-related mortality worldwide. Although surgery can be curable for a subset of patients, the five-year overall survival remains less than 15%. Despite extensive molecular characterization of pancreatic cancer, cytotoxic chemotherapy has served as the major component in therapeutic management. A major driver of pancreatic adenocarcinoma is mutations in KRAS, present in over 90% of cases. However, attempts to inhibit KRAS through upstream and downstream targets through the mitogen-activated protein kinase pathway have not been successful in the past. Despite this, multiple KRAS inhibitors have recently entered clinical trials and have shown promising results. These inhibitors have the potential to dramatically alter the landscape of treatment. In parallel, immunological approaches utilizing vaccines and bispecific antibodies are also in clinical development. Given these rapid new developments, the future of pancreatic cancer treatment will likely be determined by discovering the appropriate combinations of targeted and immune-based treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsAdenocarcinomaHumansMolecular Targeted TherapyCombined Modality TherapyProto-Oncogene Proteins p21(ras)Disease ManagementBiomarkers, TumorTreatment OutcomeMutationImmunotherapyCancer Vaccines

Stichwörter der Autor:innen

Claudin 18.2Clinical trialsKRAS inhibitionPancreatic adenocarcinoma

Substanzen

Proto-Oncogene Proteins p21(ras)Biomarkers, TumorCancer Vaccines

Autor:innen und Institutionen

  • Department of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. Chengwei.peng@northwestern.edu.
  • Department of Hematology/Oncology, NYU Langone Health, New York University, New York, NY, USA.

Zitieren

APA

Peng, C., & Oberstein, P. E. (2025). Emerging Therapeutic Approaches to Pancreatic Adenocarcinoma: Advances and Future Directions. Current Treatment Options in Oncology, 26(10), 841-865. https://doi.org/10.1007/s11864-025-01352-2

Vancouver

Peng C, Oberstein PE. Emerging Therapeutic Approaches to Pancreatic Adenocarcinoma: Advances and Future Directions. Current Treatment Options in Oncology. 2025;26(10):841-865. doi:10.1007/s11864-025-01352-2

BibTeX
@article{Peng2025,
  author = {Peng, Chengwei and Oberstein, Paul E},
  title = {Emerging Therapeutic Approaches to Pancreatic Adenocarcinoma: Advances and Future Directions},
  journal = {Current Treatment Options in Oncology},
  year = {2025},
  volume = {26},
  number = {10},
  pages = {841--865},
  doi = {10.1007/s11864-025-01352-2}
}
Kostenlos starten →